GSK PLC (GSK, Financial) has delivered a commendable performance in its first-quarter results for 2025, showing its resilience in a challenging market. Despite experiencing softer sales in its Vaccine and General Medicines segments, the company has outperformed expectations, thanks to the robust growth in its Specialty Medicines division. GSK reported a core operating profit of £2.5 billion ($3.3 billion) and a turnover of £7.5 billion ($10 billion), marking a year-over-year increase of approximately 5% and 4%, respectively.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.